Indications Reduction of risk of infection and to allow better adherence to the chemotherapeutic regimen, by decreasing the severity of cytotoxic-induced neutropenia. Acceleration of myeloid recovery in patients following autologous or syngeneic bone marrow transplantation. Adjuvant therapy in ganciclovir (DHPG)-induced neutropenia in patients with AIDS-related cytomegalovirus (CMV) retinitis in order to maintain recommended DHPG dose. See data sheet.
